Olaparib, CARBOPLATIN, Olaparib, GEMCITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK 009)

This study looks at new treatments for a type of breast cancer called Triple Negative Breast Cancer (TNBC) that has spread or come back. It compares a new drug combination with current treatments to see which works best and improves quality of life.